Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Amortizatization of Intangibles (2017 - 2025)

Protagonist Therapeutics' Amortizatization of Intangibles history spans 9 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 51.59% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $7.2 million, down 18.61%, while the annual FY2025 figure was $7.2 million, 18.61% down from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $1.3 million at Protagonist Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $2.8 million in Q3 2024 and bottomed at -$1.0 million in Q2 2022.
  • The 5-year median for Amortizatization of Intangibles is $1.3 million (2023), against an average of $1.2 million.
  • The largest annual shift saw Amortizatization of Intangibles crashed 184.05% in 2022 before it soared 2010.34% in 2024.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $584000.0 in 2021, then soared by 362.33% to $2.7 million in 2022, then rose by 4.37% to $2.8 million in 2023, then decreased by 2.06% to $2.8 million in 2024, then tumbled by 51.59% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Amortizatization of Intangibles are $1.3 million (Q4 2025), $1.7 million (Q3 2025), and $1.9 million (Q2 2025).